Sinovac’s recently opened vaccine filling and packaging facility in Beijing, China has received SFDA GMP certification, which the firm says will increase production capacity to around 40m doses a year.
The current state of pandemic influenza vaccine supplies and
capacity is shockingly insufficient, a new report has found - less
than one-fifth of needed doses would actually be available within
six months of an outbreak.
Drug giants Novartis and GlaxoSmithKline (GSK) have been awarded
contracts with the US government to develop adjuvant technology for
pandemic influenza, to potentially increase the number of doses to
be distributed among US citizens.